Skip to main content
SpringerLink
Log in

Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment

  • Review article
  • Published:
American Journal of Clinical Dermatology Aims and scope Submit manuscript

Abstract

Bullous pemphigoid (BP) is the most common autoimmune subepidermal blistering disease in Western countries, and typically affects the elderly. BP is immunologically characterized by tissue-bound and circulating autoantibodies directed against either the BP antigen 180 (BP180, or BPAG2) or the BP antigen 230 (BP230, or BPAG1e), or even both, which are components of hemidesmosomes involved in the dermal–epidermal cohesion. Risk factors for BP include old age, neurologic diseases (dementia, Parkinson’s disease, cerebrovascular disease), and some particular drugs, including loop diuretics, spironolactone and neuroleptics. The spectrum of clinical presentations is extremely broad. Clinically, BP is an intensely pruritic erythematous eruption with widespread blister formation. In the early stages, or in atypical, non-bullous variants of the disease, only excoriated, eczematous or urticarial lesions (either localized or generalized) are present. The diagnosis of BP relies on immunopathologic findings, especially based on both direct and indirect immunofluorescence microscopy observations, as well as on anti-BP180/BP230 enzyme-linked immunosorbent assays (ELISAs). BP is usually a chronic disease, with spontaneous exacerbations and remissions, which may be accompanied by significant morbidity. In the past decade, potent topical corticosteroids have emerged as an effective and safe first-line treatment for BP, but their long-term feasibility is still controversial. Newer therapeutic agents targeting molecules involved in the inflammatory cascade associated with BP represent future alternatives to classical immunosuppressant drugs for maintenance therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Stanley JR. Pemphigus and pemphigoid as paradigms of organ-specific, autoantibody-mediated diseases. J Clin Invest. 1989;83:1443–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Schmidt E, Zillikens D. Pemphigoid diseases. Lancet. 2013;381:320–32.

    Article  PubMed  Google Scholar 

  3. Stanley JR, Tanaka T, Mueller S, et al. Isolation of complementary DNA for bullous pemphigoid antigen by use of patients’ autoantibodies. J Clin Invest. 1988;82:1864–70.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Giudice GJ, Emery DJ, Diaz LA. Cloning and primary structural analysis of the bullous pemphigoid autoantigen BP180. J Invest Dermatol. 1992;99:243–50.

    Article  CAS  PubMed  Google Scholar 

  5. Zillikens D, Rose PA, Balding SD, et al. Tight clustering of extracellular BP180 epitopes recognized by bullous pemphigoid autoantibodies. J Invest Dermatol. 1997;109:573–9.

    Article  CAS  PubMed  Google Scholar 

  6. Thoma-Uszynski S, Uter W, Schwietzke S, et al. Autoreactive T and B cells from bullous pemphigoid (BP) patients recognize epitopes clustered in distinct regions of BP180 and BP230. J Immunol. 2006;176:2015–23.

    Article  CAS  PubMed  Google Scholar 

  7. Di Zenzo G, Thoma-Uszynski S, Fontao L, et al. Multicenter prospective study of the humoral autoimmune response in bullous pemphigoid. Clin Immunol. 2008;128:415–26.

    Article  PubMed  CAS  Google Scholar 

  8. Giudice GJ, Wilske KC, Anhalt GJ, et al. Development of an ELISA to detect anti-BP180 autoantibodies in bullous pemphigoid and herpes gestationis. J Invest Dermatol. 1994;102:878–81.

    Article  CAS  PubMed  Google Scholar 

  9. Zillikens D, Mascaro JM, Rose PA, Liu Z, Ewing SM, Caux F, et al. A highly sensitive enzyme-linked immunosorbent assay for the detection of circulating anti-BP180 autoantibodies in patients with bullous pemphigoid. J Invest Dermatol. 1997;109:679–83.

    Article  CAS  PubMed  Google Scholar 

  10. Kobayashi M, Amagai M, Kuroda-Kinoshita K, et al. BP180 ELISA using bacterial recombinant NC16a protein as a diagnostic and monitoring tool for bullous pemphigoid. J Dermatol Sci. 2002;30:224–32.

    Article  CAS  PubMed  Google Scholar 

  11. Di Zenzo G, Grosso F, Terracina M, et al. Characterization of the anti-BP180 autoantibody reactivity profile and epitope mapping in bullous pemphigoid patients. J Invest Dermatol. 2004;122:103–10.

    Article  PubMed  Google Scholar 

  12. Sakuma-Oyama Y, Powell AM, et al. Evaluation of a BP180-NC16a enzyme-linked immunosorbent assay in the initial diagnosis of bullous pemphigoid. Br J Dermatol. 2004;151:126–31.

    Article  CAS  PubMed  Google Scholar 

  13. Thoma-Uszynski S, Uter W, Schwietzke S, et al. BP230- and BP180-specific auto-antibodies in bullous pemphigoid. J Invest Dermatol. 2004;122:1413–22.

    Article  CAS  PubMed  Google Scholar 

  14. Tsuji-Abe Y, Akiyama M, Yamanaka Y, et al. Correlation of clinical severity and ELISA indices for the NC16A domain of BP180 measured using BP180 ELISA kit in bullous pemphigoid. J Dermatol Sci. 2005;37:145–9.

    Article  CAS  PubMed  Google Scholar 

  15. Di Zenzo G, Thoma-Uszynski S, Calabresi V, et al. Demonstration of epitope-spreading phenomena in bullous pemphigoid: results of a prospective multicenter study. J Invest Dermatol. 2011;131:2271–80.

    Article  PubMed  CAS  Google Scholar 

  16. Charneux J, Lorin J, Vitry F, et al. Usefulness of BP230 and BP180-NC16a enzyme-linked immunosorbent assays in the initial diagnosis of bullous pemphigoid: a retrospective study of 138 patients. Arch Dermatol. 2011;147:286–91.

    Article  PubMed  Google Scholar 

  17. Gammon WR, Merritt CC, Lewis DM, et al. An in vitro model of immune complex-mediated basement membrane zone separation caused by pemphigoid antibodies, leukocytes, and complement. J Invest Dermatol. 1982;78:285–90.

    Article  CAS  PubMed  Google Scholar 

  18. Sitaru C, Schmidt E, Petermann S, et al. Autoantibodies to bullous pemphigoid antigen 180 induce dermal-epidermal separation in cryosections of human skin. J Invest Dermatol. 2002;118:664–71.

    Article  CAS  PubMed  Google Scholar 

  19. Liu Z, Diaz LA, Troy JL, et al. A passive transfer model of the organ-specific autoimmune disease, bullous pemphigoid, using antibodies generated against the hemidesmosomal antigen, BP180. J Clin Invest. 1993;92:2480–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Nishie W, Sawamura D, Goto M, et al. Humanization of autoantigen. Nat Med. 2007;13:378–83.

    Article  CAS  PubMed  Google Scholar 

  21. Ujiie H, Shibaki A, Nishie W, et al. A novel active mouse model for bullous pemphigoid targeting humanized pathogenic antigen. J Immunol. 2010;184:2166–74.

    Article  CAS  PubMed  Google Scholar 

  22. Bernard P, Vaillant L, Labeille B, et al. Incidence and distribution of subepidermal autoimmune bullous skin diseases in three French regions. Bullous Diseases French Study Group. Arch Dermatol. 1995;131:48–52.

    Article  CAS  PubMed  Google Scholar 

  23. Zillikens D, Wever S, Roth A, et al. Incidence of autoimmune subepidermal blistering dermatoses in a region of central Germany. Arch Dermatol. 2005;131:957–8.

    Article  Google Scholar 

  24. Jung M, Kippes W, Messer G, et al. Increased risk of bullous pemphigoid in male and very old patients: a population-based study on incidence. J Am Acad Dermatol. 1999;41:266–8.

    Article  CAS  PubMed  Google Scholar 

  25. Gudi VS, White MI, Cruikshank N, et al. Annual incidence and mortality of bullous pemphigoid in the Grampian region of north-east Scotland. Br J Dermatol. 2005;153:424–7.

    Article  CAS  PubMed  Google Scholar 

  26. Langan SM, Smeeth L, Hubbard R, et al. Bullous pemphigoid and pemphigus vulgaris incidence and mortality in the UK: population based cohort study. BMJ. 2008;337:a180.

    Article  CAS  PubMed  Google Scholar 

  27. Marazza G, Pham HC, Schärer L, et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. Br J Dermatol. 2009;161:861–8.

    Article  CAS  PubMed  Google Scholar 

  28. Joly P, Baricault S, Sparsa A, et al. Incidence and mortality of bullous pemphigoid in France. J Invest Dermatol. 2012;132:1998–2004.

    Article  CAS  PubMed  Google Scholar 

  29. Brick K, Weaver C, Lohse CM, et al. Incidence of bullous pemphigoid and mortality of patients with bullous pemphigoid in Olmsted County, Minnesota, 1960 through 2009. J Am Acad Dermatol. 2014;71:92–9.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Försti AK, Jokelainen J, Timonen M, Tasanen K. Increasing incidence of bullous pemphigoid in Northern Finland: a retrospective study database study in Oulu University Hospital. Br J Dermatol. 2014;171:1223–6.

    Article  PubMed  Google Scholar 

  31. Korman N. Bullous pemphigoid. J Am Acad Dermatol. 1987;16:907–24.

    Article  CAS  PubMed  Google Scholar 

  32. Waisbourd-Zinman O, Ben-Amitai D, Cohen AD, et al. Bullous pemphigoid in infancy: clinical and epidemiologic characteristics. J Am Acad Dermatol. 2008;58:41–8.

    Article  PubMed  Google Scholar 

  33. Schweiger-Briel A, Moellmann C, Mattulat B, et al. Bullous pemphigoid in infants: characteristics, diagnosis and treatment. Orphanet J Rare Dis. 2014;9:185.

    Article  Google Scholar 

  34. Di Zenzo G, Marazza G, Borradori L. Bullous pemphigoid: physiopathology, clinical features and management. Adv Dermatol. 2007;23:257–88.

    Article  PubMed  Google Scholar 

  35. Schmidt E, Benoit S, Brocker EB. Bullous pemphigoid with localized umbilical involvement. Acta Derm Venereol. 2009;89:419–20.

    Article  PubMed  Google Scholar 

  36. Callens A, Vaillant L, Machet MC, et al. Localized atypical pemphigoid on lymphedema following radiotherapy. Acta Derm Venereol. 1993;73:461–4.

    CAS  PubMed  Google Scholar 

  37. Borradori L, Prost C, Woklenstein P, et al. Localized pretibial bullous pemphigoid and pemphigoid nodularis: report of a case. J Am Acad Dermatol. 1992;27:863–7.

    Article  CAS  PubMed  Google Scholar 

  38. Descamps V, Flageul B, Vignon-Pennamen D, et al. Dyshidrosiform pemphigoid: report of three cases. J Am Acad Dermatol. 1992;26:651–2.

    Article  CAS  PubMed  Google Scholar 

  39. Farrell AM, Kirtschig G, Dalziel KL, et al. Childhood vulval pemphigoid: a clinical and immunopathological study of five patients. Br J Dermatol. 1999;140:308–12.

    Article  CAS  PubMed  Google Scholar 

  40. Komine M, Nashiro K, Asahina K, et al. Vesicular pemphigoid. Int J Dermatol. 1992;31:868–70.

    Article  CAS  PubMed  Google Scholar 

  41. Delpuget-Martin N, Bernard P, Bedane C, et al. Pemphigoïde végétante. Ann Dermatol Vénéréol. 1997;124:467–9.

    Google Scholar 

  42. Cliff S, Holden CA. Pemphigoid nodularis: a report of three cases and review of the literature. Br J Dermatol. 1997;136:398–401.

    Article  CAS  PubMed  Google Scholar 

  43. Korman NJ, Woods SG. Erythrodermic bullous pemphigoid is a clinical variant of bullous pemphigoid. Br J Dermatol. 1995;133:967–71.

    Article  CAS  PubMed  Google Scholar 

  44. Cordel N, Courville P, Martel P, et al. Extensive erosive bullous pemphigoid: an atypical and serious clinical variant. Br J Dermatol. 2002;146:537–9.

    Article  CAS  PubMed  Google Scholar 

  45. Cordel N, Chosidow O, Hellot M-F, et al. Neurological disorders in patients with bullous pemphigoid. Dermatology. 2007;215:187–91.

    Article  PubMed  Google Scholar 

  46. Stinco G, Codutti R, Scarbolo M, Valent F, Patrone P. A retrospective epidemiological study on the association of bullous pemphigoid and neurological diseases. Acta Derm Venereol. 2005;85:136–9.

    Article  PubMed  Google Scholar 

  47. Chosidow O, Doppler V, Bensimon G, et al. Bullous pemphigoid and amyotrophic lateral sclerosis: a new clue for understanding the bullous disease? Arch Dermatol. 2000;136:521–4.

    Article  CAS  PubMed  Google Scholar 

  48. Jedlickova H, Hlubinka M, Pavlik T, et al. Bullous pemphigoid and internal diseases: a case–control study. Eur J Dermatol. 2010;20:96–101.

    PubMed  Google Scholar 

  49. Taghipour K, Chi C-C, Vincent A, Groves RW, Venning V, Wojnarowska F. The association of bullous pemphigoid with cerebrovascular disease and dementia: a case–control study. Arch Dermatol. 2010;146:1251–4.

    Article  PubMed  Google Scholar 

  50. Chen YJ, Wu CY, Lin MW, Chen TJ, Liao KK, Chen YC, et al. Comorbidity profiles among patients with bullous pemphigoid: a nationwide population-based study. Br J Dermatol. 2011;165:593–9.

    Article  CAS  PubMed  Google Scholar 

  51. Langan SM, Groves RW, West J. The relationship between neurological disease and bullous pemphigoid: a population-based case–control study. J Invest Dermatol. 2011;131:631–6.

    Article  CAS  PubMed  Google Scholar 

  52. Bastuji-Garin S, Joly P, Lemordant P, et al. Risk factors for bullous pemphigoid in the elderly. A prospective case–control study. J Invest Dermatol. 2011;131:637–43.

    Article  CAS  PubMed  Google Scholar 

  53. Brick K, Weaver CH, Savica R, et al. A population-based study of the association between bullous pemphigoid and neurologic disorders. J Am Acad Dermatol. 2014;71:1191–7.

    Article  PubMed  PubMed Central  Google Scholar 

  54. Casas-de-la-Asuncion E, Ruano-Ruiz J, Rodriguez-Martin AM, et al. Association between bullous pemphigoid and neurologic diseases: a case–control study in Portuguese patients. Actas Dermosifiliogr. 2014;105:860–5.

    Article  CAS  PubMed  Google Scholar 

  55. Texeira VB, Cabral R, Brites MM, et al. Bullous pemphigoid and comorbidities: a case–control study in Portuguese patients. An Bras Dermatol. 2014;89:274–9.

    Article  Google Scholar 

  56. Chevalier V, Barbe C, Reguiai Z, et al. Impact of neurological diseases on the prognosis of bullous pemphigoid: a retrospective study of 178 patients [in French]. Ann Dermatol Vénéréol. 2016;143:179–86.

    Article  CAS  PubMed  Google Scholar 

  57. Lai YC, Yew YW, Lambert WC. Bullous pemphigoid and its association with neurological diseases: a systematic review and meta-analysis. J Eur Acad Dermatol Venereol. 2016;30:2007–15.

    Article  CAS  PubMed  Google Scholar 

  58. Seppanen A, Suuronen T, Hofmann SC, et al. Distribution of collagen XVII in the human brain. Brain Res. 2007;1158:50–6.

    Article  PubMed  CAS  Google Scholar 

  59. Di Zenzo G, Della Torre R, Zambruno G, Borradori L. Bullous pemphigoid: from the clinic to the bench. Clin Dermatol. 2012;30:3–16.

    Article  PubMed  Google Scholar 

  60. Vassilieva S. Drug-induced pemphigoid: bullous and cicatricial. Clin Dermatol. 1998;16:379–87.

    Article  Google Scholar 

  61. Stravopoulos PG, Soura E, Antoniou C. Drug-induced pemphigoid. J Eur Acad Dermatol. 2014;28:1133–40.

    Article  Google Scholar 

  62. Bastuji-Garin S, Joly P, Picard-Dahan C, et al. Drugs associated with bullous pemphigoid. A case–control study. Arch Dermatol. 1996;132:272–6.

    Article  CAS  PubMed  Google Scholar 

  63. Lloyd-Lavery A, Chi CC, Wojnarowska F, Taghipour K. The associations between bullous pemphigoid and drug use: a UK case–control study. JAMA Dermatol. 2013;149:58–62.

    Article  PubMed  Google Scholar 

  64. Bene J, Moulis G, Bennani I, et al. Bullous pemphigoid and dipeptidyl peptidase IV inhibitors: a case-noncase study in the French Pharmacovigilance database. Br J Dermatol. 2016;175(2):296–301.

    Article  CAS  PubMed  Google Scholar 

  65. Ruocco E, Wolf R, Caccavale S, et al. Bullous pemphigoid: associations and management guidelines: facts and controversies. Clin Dermatol. 2013;31:400–12.

    Article  PubMed  Google Scholar 

  66. Venning VA, Vojnarowska F. The association between and malignant disease: a case–control study. Br J Dermatol. 1990;123:439–45.

    Article  CAS  PubMed  Google Scholar 

  67. Lindelof B, Islam N, Eklund G, et al. Pemphigoid and cancer. Arch Dermatol. 1990;126:66–8.

    Article  CAS  PubMed  Google Scholar 

  68. Ogawa H, Sakuma M, Morioka S, et al. The incidence of internal malignancies in pemphigus and bullous pemphigoid in Japan. J Dermatol Sci. 1995;9:136–41.

    Article  CAS  PubMed  Google Scholar 

  69. Ong E, Goldacre R, Hoang U, et al. Associations between bullous pemphigoid and primary malignant cancers: an English national record linkage study, 1999–2011. Arch Dermatol Res. 2014;306:75–80.

    Article  PubMed  Google Scholar 

  70. Schulze F, Neumann K, Recke A, et al. Malignancies in pemphigus and pemphigoid diseases. J Invest Dermatol. 2015;135:1445–7.

    Article  CAS  PubMed  Google Scholar 

  71. Kirtschig G, Chow ET, Venning VA, et al. Acquired subepidermal bullous diseases associated with psoriasis: a clinical, immunopathological and immunogenetic study. Br J Dermatol. 1996;135:738–45.

    Article  CAS  PubMed  Google Scholar 

  72. Wilczek A, Sticherling M. Concomitant psoriasis and bullous pemphigoid: coincidence or pathogenic relationship? Int J Dermatol. 2006;45:1353–7.

    Article  PubMed  Google Scholar 

  73. Le Jan S, Plée J, Vallerand D, et al. Innate immune cell-produced IL-17 sustains inflammation in bullous pemphigoid. J Invest Dermatol. 2014;134:2908–17.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  74. Shipman AR, Cooper S, Wojnarowska F. Autoreactivity to bullous pemphigoid 180: is this the link between subepidermal blistering diseases and oral lichen planus? Clin Exp Dermatol. 2011;36:267–9.

    Article  CAS  PubMed  Google Scholar 

  75. Taylor G, Venning V, Wojnarowska F, et al. Bullous pemphigoid and autoimmunity. J Am Acad Dermatol. 1993;29:181–4.

    Article  CAS  PubMed  Google Scholar 

  76. Chuang TY, Korkij W, Soltani K, et al. Increased frequency of diabetes mellitus in patients with bullous pemphigoid: a case–control study. J Am Acad Dermatol. 1984;11:1099–102.

    Article  CAS  PubMed  Google Scholar 

  77. Oh DD, Zhao CY, Murrell DF. A review of case–control studies on the risk factors for the development of auto-immune blistering diseases. J Eur Acad Dermatol. 2016;30:595–603.

    Article  CAS  Google Scholar 

  78. Murrell DF, Daniel BS, Joly P, et al. Definitions and outcome measures for bullous pemphigoid: recommendations by an international panel of experts. J Am Acad Dermatol. 2012;66:479–85.

    Article  PubMed  Google Scholar 

  79. Levy-Sitbon C, Barbe C, Plee J, et al. Assessment of bullous pemphigoid disease area index during treatment: a prospective study of 30 patients. Dermatology. 2014;229:116–22.

    Article  PubMed  Google Scholar 

  80. Joly P, Roujeau JC, Benichou J, et al. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid. N Engl J Med. 2002;346:321–7.

    Article  CAS  PubMed  Google Scholar 

  81. Joly P, Roujeau JC, Benichou J, et al. A comparison of two regimens of topical corticosteroids in the treatment of patients with bullous pemphigoid: a multicenter randomized study. J Invest Dermatol. 2009;129:1681–7.

    Article  CAS  PubMed  Google Scholar 

  82. Vaillant L, Bernard P, Joly P, et al. Evaluation of clinical criteria for diagnosis of bullous pemphigoid. Arch Dermatol. 1998;134:1075–80.

    Article  CAS  PubMed  Google Scholar 

  83. Joly P, Courville P, Lok C, et al. Clinical criteria for the diagnosis of bullous pemphigoid: a reevaluation according to immunoblot analysis of patient sera. Dermatology. 2004;208:16–20.

    Article  CAS  PubMed  Google Scholar 

  84. Joly P, Benichou J, Lok C, et al. Prediction of survival for patients with bullous pemphigoid: a prospective study. Arch Dermatol. 2005;141:691–8.

    Article  PubMed  Google Scholar 

  85. Bernard P, Reguiai Z, Tancrède-Bohin E, et al. Risk factors for relapse in patients with bullous pemphigoid in clinical remission: a multicenter, prospective, cohort study. Arch Dermatol. 2009;145:537–42.

    Article  PubMed  Google Scholar 

  86. Fichel F, Barbe C, Joly P, et al. Clinical and immunologic factors associated with bullous pemphigoid relapse during the first year of treatment: a multicenter, prospective study. JAMA Dermatol. 2014;150:25–33.

    Article  PubMed  Google Scholar 

  87. della Torre R, Combescure C, Cortes B, et al. Clinical presentation and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort. Br J Dermatol. 2012;167:1111–7.

    Article  CAS  PubMed  Google Scholar 

  88. Lipsker D, Borradori L. Bullous pemphigoid: what are you ? Urgent need of definitions and diagnostic criteria. Dermatology. 2010;221:131–4.

    Article  PubMed  Google Scholar 

  89. Schmidt E, della Torre R, Borradori L. Clinical features and practical diagnosis of bullous pemphigoid. Clin Dermatol. 2011;29:427–38.

    Article  CAS  Google Scholar 

  90. Gammon WR, Kowalewski C, Chorzelski TP, et al. Direct immunofluorescence studies of sodium chloride-separated skin in the differential diagnosis of bullous pemphigoid and epidermolysis bullosa acquisita. J Am Acad Dermatol. 1990;22:664–70.

    Article  CAS  PubMed  Google Scholar 

  91. Terra JB, Meijer JM, Jonkman MF, Diercks GFH. The n- vs. u-serration is a learnable criterion to differentiate pemphigoid from epidermolysis bullosa acquisita in direct immunofluorescence serration-pattern analysis. Br J Dermatol. 2013;169:100–5.

    Article  CAS  PubMed  Google Scholar 

  92. De Jong MC, Bruins S, Heeres K, et al. Bullous pemphigoid and epidermolysis bullosa acquisita. Differentiation by fluorescence overlay antigen mapping. Arch Dermatol. 1996;132:151–7.

    Article  PubMed  Google Scholar 

  93. Kelly SE, Wojnarowska F. The use of chemically split tissue in the detection of circulating anti-basement membrane zone antibodies in bullous pemphigoid and cicatricial pemphigoid. Br J Dermatol. 1988;118:31–40.

    Article  CAS  PubMed  Google Scholar 

  94. Gammon WR, Fine JD, Forbes M, et al. Immunofluorescence on split skin for the detection and differentiation of basement membrane zone autoantibodies. J Am Acad Dermatol. 1992;27:79–87.

    Article  CAS  PubMed  Google Scholar 

  95. Sardy M, Kostaki D, Varga R, et al. Comparative study of direct and indirect immunofluorescence and of bullous pemphigoid 180 and 230 enzyme-linked immunosorbent assays for diagnosis of bullous pemphigoid. J Am Acad Dermatol. 2013;69:748–53.

    Article  CAS  PubMed  Google Scholar 

  96. van Beek N, Rentzsch K, Probst C, et al. Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy. Orphanet J Rare Dis. 2012;7:49.

    Article  PubMed  PubMed Central  Google Scholar 

  97. Labib RS, Anhalt GJ, Patel HP, et al. Molecular heterogeneity of the bullous pemphigoid antigens as detected by immunoblotting. J Immunol. 1986;136:1231–5.

    CAS  PubMed  Google Scholar 

  98. Bernard P, Didierjean L, Denis F, et al. Heterogeneous bullous pemphigoid antibodies : detection and characterization by immunoblotting when absent by indirect immunofluorescence. J Invest Dermatol. 1989;92:171–5.

    Article  CAS  PubMed  Google Scholar 

  99. Bernard P, Aucouturier P, Denis F, et al. Immunoblot analysis of IgG subclasses of circulating antibodies in bullous pemphigoid. Clin Immunol Immunopathol. 1990;54:484–94.

    Article  CAS  PubMed  Google Scholar 

  100. Gohestani R, Kanitakis J, Nicolas JF, et al. Comparative sensitivity of indirect immunofluorescence to immunoblot assay for the detection of circulating antibodies to bullous pemphigoid antigens 1 and 2. Br J Dermatol. 1996;135:74–9.

    Article  Google Scholar 

  101. Barnadas MA, Rubiales MV, González MJ, et al. Enzyme-linked immunosorbent assay (ELISA) and indirect immunofluorescence testing in a bullous pemphigoid and pemphigoid gestationis. Int J Dermatol. 2008;47:1245–9.

    Article  PubMed  Google Scholar 

  102. Schmidt E, Obe K, Bröcker EB, Zillikens D. Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid. Arch Dermatol. 2000;136:174–8.

    Article  CAS  PubMed  Google Scholar 

  103. Roussel A, Benichou J, Randriamanantany ZA, et al. Enzyme-linked immunosorbent assay for the combination of bullous pemphigoid antigens 1 and 2 in the diagnosis of bullous pemphigoid. Arch Dermatol. 2011;147:293–8.

    Article  PubMed  Google Scholar 

  104. Kromminga A, Sitaru C, Hagel C, et al. Development of an ELISA for the detection of autoantibodies to BP230. Clin Immunol. 2004;111:146–52.

    Article  CAS  PubMed  Google Scholar 

  105. Tampoia M, Lattanzi V, Zucano A, et al. Evaluation of a new ELISA assay for detection of BP230 autoantibodies in bullous pemphigoid. Ann N Y Acad Sci. 2009;1173:15–20.

    Article  CAS  PubMed  Google Scholar 

  106. Le Saché-de Peufeilhoux L, Ingen-Housz-Oro S, Hue S, et al. The value of BP230 enzyme-linked immunosorbent assay in the diagnosis and immunological follow-up of bullous pemphigoid. Dermatology. 2012;224:154–9.

    Article  CAS  Google Scholar 

  107. Wieland CN, Confere NI, Gibson LE, et al. Anti-bullous pemphigoid 180 and 230 antibodies in a sample of unaffected subjects. Arch Dermatol. 2010;146:21–5.

    PubMed  Google Scholar 

  108. van Beek N, Dohse A, Riechert F, et al. Serum autoantibodies against the dermal-epidermal junction in patients with chronic pruritic disorders, elderly individuals and blood donors prospectively recruited. Br J Dermatol. 2014;170:943–7.

    Article  PubMed  CAS  Google Scholar 

  109. Meijer JM, Lamberts A, Pas HH, Jonkman MF. Significantly higher prevalence of circulating bullous pemphigoid-specific IgG autoantibodies in elderly patients with a non-bullous skin disorder. Br J Dermatol. 2015;173:1274–6.

    Article  CAS  PubMed  Google Scholar 

  110. Bernard P, Antonicelli F, Bedane C, et al. Prevalence and clinical significance of anti-Laminin 332 autoantibodies detected by a novel enzyme-linked immunosorbent assay in mucous membrane pemphigoid. JAMA Dermatol. 2013;149:533–40.

    Article  CAS  PubMed  Google Scholar 

  111. Chan LS, Ahmed AR, Anhalt GJ, et al. The first international consensus on mucous membrane pemphigoid: definition, diagnostic criteria, pathogenic factors, medical treatment, and prognostic indicators. Arch Dermatol. 2002;138:370–9.

    PubMed  Google Scholar 

  112. Ghohestani RF, Nicolas JF, Rousselle P, Claudy AL. Diagnostic value of indirect immunofluorescence on sodium chloride-split skin in differential diagnosis of subepidermal autoimmune bullous dermatoses. Arch Dermatol. 1997;133:1102–7.

    Article  CAS  PubMed  Google Scholar 

  113. Schmidt E, Skrobek C, Kromminga A, et al. Cicatricial pemphigoid: IgA and IgG autoantibodies target epitopes on both intra- and extracellular domains of bullous pemphigoid antigen 180. Br J Dermatol. 2001;145:778–83.

    Article  CAS  PubMed  Google Scholar 

  114. Yeh SW, Usman AQ, Ahmed AR. Profile of autoantibody to basement membrane zone proteins in patients with mucous membrane pemphigoid: long-term follow up and influence of therapy. Clin Immunol. 2004;112:268–72.

    Article  CAS  PubMed  Google Scholar 

  115. Oyama N, Setterfield JF, Powell AM, et al. Bullous pemphigoid antigen II (BP180) and its soluble extracellular domains are major autoantigens in mucous membrane pemphigoid: the pathogenic relevance to HLA class II alleles and disease severity. Br J Dermatol. 2006;154:90–8.

    Article  CAS  PubMed  Google Scholar 

  116. Bruch-Gerharz D, Hertl M, Ruzicka T. Mucous membrane pemphigoid: clinical aspects, immunopathological features and therapy. Eur J Dermatol. 2007;17:191–200.

    PubMed  Google Scholar 

  117. Ludwig R. Clinical presentation, pathogenesis, diagnosis, and treatment of epidermolysis bullosa acquisita. ISRN Dermatol. 2013;2013:812029.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  118. Chen M, Kim GH, Prakash I, Woodley DT. Epidermolysis bullosa acquisita: autoimmunity against to anchoring fibril collagen. Autoimmunity. 2012;45:91–101.

    Article  CAS  PubMed  Google Scholar 

  119. Komorowski L, Müller R, Vorobyev A. Sensitive and specific assays for routine serological diagnosis of epidermolysis bullosa acquisita. J Am Acad Dermatol. 2013;68:e89–95.

    Article  CAS  PubMed  Google Scholar 

  120. Yaoita H, Briggaman RA, Lawley TH. Epidermolysis bullosa acquisita : ultrastructural and immunological studies. J Invest Dermatol. 1981;76:288–92.

    Article  CAS  PubMed  Google Scholar 

  121. Dainichi T, Koga H, Tsuji T, et al. From anti-P200 pemphigoid to anti laminin gamma1 pemphigoid. J Dermatol. 2010;37:231–8.

    Article  CAS  PubMed  Google Scholar 

  122. Groth S, Recke A, Vafia K, et al. Development of a simple ELISA for the detection of autoantibodies in anti-P200 pemphigoid. Br J Dermatol. 2011;164:76–82.

    Article  CAS  PubMed  Google Scholar 

  123. Danichi T, Kurono S, Ohyama B, et al. Anti-laminin gamma-1 pemphigoid. Proc Natl Acad Sci USA. 2009;106:2800–5.

    Article  Google Scholar 

  124. Rieckoff-Cantoni L, Bernard P, Didierjean L, et al. Frequency of bullous pemphigoid-like antibodies as detected by western blotting in pruritic dermatoses. Arch Dermatol. 1992;128:791–4.

    Article  Google Scholar 

  125. Baaker C, Terra JB, Jonkman MF. Bullous pemphigoid as pruritus in the elderly. A common presentation. JAMA Dermatol. 2014;149:950–3.

    Article  Google Scholar 

  126. Kyriakis KP, Paparizos VA, Panteleos DN, Tosca AD. Re-evaluation of the natural course of bullous pemphigoid. A prospective study. Int J Dermatol. 1999;38:909–13.

    Article  CAS  PubMed  Google Scholar 

  127. Bernard P, Bedane C, Bonnetblanc JM. Anti-BP180 autoantibodies as a marker of poor vital prognosis in bullous pemphigoid: a cohort analysis of 94 elderly patients. Br J Dermatol. 1997;136:694–8.

    Article  CAS  PubMed  Google Scholar 

  128. Colbert RL, Allen DM, Eastwood D, et al. Mortality rate of bullous pemphigoid in a US medical center. J Invest Dermatol. 2004;122:1091–5.

    Article  CAS  PubMed  Google Scholar 

  129. Cortés B, Khelifa E, Clivaz L, et al. Mortality rate in bullous pemphigoid: a retrospective monocentric cohort study. Dermatology. 2012;225:320–5.

    Article  PubMed  Google Scholar 

  130. Roujeau JC, Lok C, Bastuji-Garin S, et al. High risk of death in elderly patients with extensive bullous pemphigoid. Arch Dermatol. 1998;134:465–9.

    Article  CAS  PubMed  Google Scholar 

  131. Rzany B, Partscht K, Jung M, et al. Risk factors for lethal outcome inpatients with bullous pemphigoid: low serum albumin level, high dosage of glucocorticosteroids, and old age. Arch Dermatol. 2002;138:903–8.

    Article  PubMed  Google Scholar 

  132. Kirtschig G, Middleton P, Bennett C, et al. Interventions for bullous pemphigoid. Cochrane Database Syst Rev. 2010;(10):CD002292.

  133. Burton JL, Harman RM, Peachey RD, et al. A controlled trial of azathioprine in the treatment of pemphigoid [proceedings]. Br J Dermatol. 1978;99:14.

    Article  CAS  PubMed  Google Scholar 

  134. Morel P, Guillaume JC. Treatment of bullous pemphigoid with prednisolone only: 0.75 mg/kg/day versus 1.25 mg/kg/day. A multicenter randomized study. Ann Dermatol Venereol. 1984;111:925–8.

    CAS  PubMed  Google Scholar 

  135. Roujeau JC, Guillaume JC, Morel P, et al. Plasma exchange in bullous pemphigoid. Lancet. 1984;2:486–8.

    Article  CAS  PubMed  Google Scholar 

  136. Guillaume JC, Vaillant L, Bernard P, et al. Controlled trial of azathioprine and plasma exchange in addition to prednisolone in the treatment of bullous pemphigoid. Arch Dermatol. 1993;129:49–53.

    Article  CAS  PubMed  Google Scholar 

  137. Dreno B, Sassolas B, Lacour P, et al. Methylprednisolone versus prednisolone methylsulfobenzoate in pemphigoid: a comparative multicenter study. Ann Dermatol Venereol. 1993;120:518–21.

    CAS  PubMed  Google Scholar 

  138. Fivenson DP, Breneman DL, Rosen GB, et al. Nicotinamide and tetracycline therapy of bullous pemphigoid. Arch Dermatol. 1994;130:753–8.

    Article  CAS  PubMed  Google Scholar 

  139. Liu BG, Li ZY, Di M. Effect of Jingui Shenqi pill combined prednisone on expression of glucocorticoid receptor and its clinical effect in treating bullous pemphigoid patients. Zhonqqo Zhong Xi Ji Jie He Za Zhi. 2006;26:881–4.

    Google Scholar 

  140. Beissert S, Werfel T, Frieling U, et al. A comparison of oral methylprednisolone plus azathioprine or mycophenolate mofetil for the treatment of bullous pemphigoid. Arch Dermatol. 2007;143:1536–42.

    Article  CAS  PubMed  Google Scholar 

  141. Daniel BS, Borradori L, Hall RP, Murrell DF. Evidence-based management of bullous pemphigoid. Dermatol Clin. 2011;29:613–20.

    Article  CAS  PubMed  Google Scholar 

  142. Bernard P, Bedane C, Prost C, et al. Bullous pemphigoid. Guidelines for the diagnosis and treatment. Centres de référence des maladies bulleuses auto-immunes. Société Française de Dermatologie [in French]. Ann Dermatol Venereol. 2011;138:247–51.

    Article  CAS  PubMed  Google Scholar 

  143. Venning VA, Thagipour K, Mohd Mustapa MF, et al. British Association of Dermatologists’ guidelines for the management of bullous pemphigoid. Br J Dermatol. 2012;167:1200–14.

    Article  CAS  PubMed  Google Scholar 

  144. Feliciani C, Joly P, Jonkman MF, et al. Management of bullous pemphigoid: the European Dermatology Forum consensus in collaboration with the European Academy of Dermatology and Venereology. Br J Dermatol. 2015;172:867–77.

    Article  CAS  PubMed  Google Scholar 

  145. Lebrun-Vignes V, Roujeau JC, Bernard P, et al. Prednisone is more effective than prednisolone metasulfobenzoate in the treatment of bullous pemphigoid. Arch Dermatol. 1999;135:89–90.

    Article  CAS  PubMed  Google Scholar 

  146. Terra JB, Potze WJ, Jonkman MF. Whole body application of a potent topical corticosteroid for bullous pemphigoid. J Eur Acad Dermatol Venereol. 2014;28:712–8.

    Article  CAS  PubMed  Google Scholar 

  147. Sobocinski V, Duvert-Lehembre S, Bubenheim M, et al. Assessment of compliance with topical corticosteroids in bullous pemphigoid patients. Br J Dermatol. 2016;174:919–21.

    Article  CAS  PubMed  Google Scholar 

  148. Bézier M, Reguiai Z, Vitry F, et al. Usefulness of thiopurine S-methyltransferase genotypic analysis in patients with autoimmune bullous diseases: a preliminary study. Eur J Dermatol. 2008;18:512–7.

    PubMed  Google Scholar 

  149. Paul MA, Jorizzo JL, Fleischer AB Jr, White WL. Low-dose methotrexate treatment in elderly patients with bullous pemphigoid. J Am Acad Dermatol. 1994;31:620–5.

    Article  CAS  PubMed  Google Scholar 

  150. Kjellman P, Eriksson H, Berg P. A retrospective analysis of patients with bullous pemphigoid treated with methotrexate. Arch Dermatol. 2008;144:612–6.

    Article  CAS  PubMed  Google Scholar 

  151. Gurcan HM, Ahmed AR. Analysis of current data on the use of methotrexate in the treatment of pemphigus and pemphigoid. Br J Dermatol. 2009;161:723–31.

    Article  CAS  PubMed  Google Scholar 

  152. Du-Thanh A, Merlet S, Maillard H, et al. Combined treatment with low-dose methotrexate and initial short-term superpotent topical steroids in bullous pemphigoid : an open, multicenter, retrospective study. Br J Dermatol. 2011;165:1337–43.

    Article  CAS  PubMed  Google Scholar 

  153. Chave TA, Mortimer NJ, ShaH DS, Hutchinson PE. Chlorambucil as steroid-sparing agent in bullous pemphigoid. Br J Dermatol. 2004;151:1107–8.

    Article  CAS  PubMed  Google Scholar 

  154. Gual A, Iranzo P, Mascaro JM. Treatment of bullous pemphigoid with low-dose cyclophosphamide: a case series of 20 patients. J Eur Acad Dermatol. 2014;28:814–8.

    Article  CAS  Google Scholar 

  155. Chalmers JR, Wojnarowska F, Kirtschig G, et al. A randomized controlled trial to compare the safety and effectiveness of doxycycline (200 mg daily) with oral prednisolone (0.5 mk kg−1 daily) for initial treatment of bullous pemphigoid: a protocol for the Bullous Pemphigoid Steroids and Tetracyclines (BLISTER) Trial. Br J Dermatol. 2015;173:227–34.

    Article  CAS  PubMed  Google Scholar 

  156. Venning VA, Millard PR, Wojnarowska F. Dapsone as first line therapy for bullous pemphigoid. Br J Dermatol. 1989;120:83–92.

    Article  CAS  PubMed  Google Scholar 

  157. Bouscarat F, Chosidow O, Picard-Dahan C, et al. Treatment of bullous pemphigoid with dapsone: retrospective study of thirty-six cases. J Am Acad Dermatol. 1996;34:683–4.

    Article  CAS  PubMed  Google Scholar 

  158. Chu J, Bradley M, Marinkovitch MP. Topical tacrolimus is a useful adjunctive therapy for bullous pemphigoid. Arch Dermatol. 2003;139:813–5.

    Article  PubMed  Google Scholar 

  159. Ko MJ, Chu CY. Topical tacrolimus therapy for localized bullous pemphigoid. Br J Dermatol. 2003;149:1079–81.

    Article  PubMed  Google Scholar 

  160. Harman KE, Black MM. High-dose intravenous immune globulin for the treatment of autoimmune blistering diseases: an evaluation of its use in 14 cases. Br J Dermatol. 1999;140:865–74.

    Article  CAS  PubMed  Google Scholar 

  161. Ahmed AR. Intravenous immunoglobulin therapy for patients with bullous pemphigoid unresponsive to conventional immunosuppressive treatment. J Am Acad Dermatol. 2001;45:825–35.

    Article  CAS  PubMed  Google Scholar 

  162. Gaitanis G, Alexis I, Pelidou SH, et al. High dose intravenous immunoglobulins in the treatment of adult patients with bullous pemphigoid. Eur J Dermatol. 2012;22:363–9.

    CAS  PubMed  Google Scholar 

  163. Guillot B, Donadio D, Guilhou JJ, et al. Long term plasma exchange therapy in bullous pemphigoid. Acta Derm Venereol. 1986;66:73–5.

    CAS  PubMed  Google Scholar 

  164. Müller PA, Bröcker EB, Klinker E, et al. Adjuvant treatment of recalcitrant bullous pemphigoid with immunoadsorption. Dermatology. 2012;224:224–7.

    Article  PubMed  Google Scholar 

  165. Schmidt E, Seitz CS, Benoit S, et al. Rituximab in autoimmune bullous diseases: mixed responses and adverse effects. Br J Dermatol. 2007;156:352–6.

    Article  CAS  PubMed  Google Scholar 

  166. Reguiai Z, Tchen T, Perceau G, et al. Efficacy of rituximab in a case of refractory bullous pemphigoid. Ann Dermatol Venereol. 2009;136:431–4.

    Article  CAS  PubMed  Google Scholar 

  167. Kasperkiewicz M, Shimanovitch I, Ludwig R, et al. Rituximab for treatment-refractory pemphigus and pemphigoid. J Am Acad Dermatol. 2011;65:552–8.

    Article  CAS  PubMed  Google Scholar 

  168. Hall RP 3rd, Streilein RD, Hannah DL, McNair PD, Fairley JA, Ronaghy A, et al. Association of serum B-cell activating factor level and proportion of memory and transitional B cells with clinical response after rituximab treatment of bullous pemphigoid patients. J Invest Dermatol. 2013;133:2786–8.

    Article  CAS  PubMed  Google Scholar 

  169. Yamauchi PS, Lowe NJ, Gindi V. Treatment of coexisting bullous pemphigoid and psoriasis with the tumour necrosis factor antagonist etanercept. J Am Acad Dermatol. 2006;54:S121–2.

    Article  PubMed  Google Scholar 

  170. Ahmed AR, Shetty S, Spigelman S. Treatment of recalcitrant bullous pemphigoid with a novel protocol: a retrospective study with a 6-year follow-up. J Am Acad Dermatol. 2016;74:700–8.

    Article  PubMed  Google Scholar 

  171. Fairley J, Baum CL, Brandt DS, et al. Pathogenicity of IgE autoimmunity: successful treatment of bullous pemphigoid with omalizumab. J Allergy Clin Immunol. 2009;123:704–5.

    Article  PubMed  PubMed Central  Google Scholar 

  172. Yu KK, Crew AB, Messingham KA, Fairley JA, Woodley DT. Omalizumab therapy for bullous pemphigoid. J Am Acad Dermatol. 2014;71:468–74.

    Article  CAS  PubMed  Google Scholar 

  173. Boussemart L, Jacobelli Batteux F, et al. Auto-immune bullous skin diseases occurring under anti-tumor necrosis factor therapy. Dermatology. 2010;221:201–5.

    Article  CAS  PubMed  Google Scholar 

  174. Plée J, Le Jan S, Giustiniani J, et al. Integrating longitudinal serum IL-17 and IL-23 follow-up, along with autoantibodies, contributes to predict bullous pemphigoid outcome. Sci Rep. 2015;5:18001.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  175. Loget J, Plee J, Antonicelli F, Bernard P. A successful treatment with ustekinumab in a case of relapsing bullous pemphigoid associated with psoriasis. J Eur Acad Dermatol. Epub 12 Oct 2016. doi:10.1111/jdv.14002.

  176. Nakayama C, Fujita Y, Watanabe M, et al. Development of bullous pemphigoid during treatment of psoriatic onycho-pachydermo periostitis with ustekinumab. J Dermatol. 2015;42:996–8.

    Article  CAS  PubMed  Google Scholar 

  177. Cai SC, Lim YL, Li W, et al. Anti-BP180 NC16A titres as an indicator of disease activity and outcome in Asian with bummous pemphigoid. Ann Acad Med Singap. 2015;44:119–26.

    PubMed  Google Scholar 

  178. Ingen-Housz-Oro S, Plee J, Belmondo T, et al. Positive direct immunofluorescence is of better value than ELISA-BP180 and ELISA-BP230 values for the prediction of relapse after treatment cessation in bullous pemphigoid: a retrospective study of 97 patients. Dermatology. 2015;231:50–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Dermatology and Reference Centre for Autoimmune Bullous Diseases, Robert Debré Hospital, University of Reims Champagne-Ardenne, Cedex, France

    Philippe Bernard

  2. Laboratory of Dermatology, EA7319 Derm-I-C, University of Reims Champagne-Ardenne, 51 rue Cognacq Jay, 51095, Cedex, France

    Frank Antonicelli

Authors
  1. Philippe Bernard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Frank Antonicelli
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Philippe Bernard.

Ethics declarations

Funding

No funding was received for the preparation of this review.

Conflict of interest

Philippe Bernard and Frank Antonicelli have no conflicts of interest to declare.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bernard, P., Antonicelli, F. Bullous Pemphigoid: A Review of its Diagnosis, Associations and Treatment. Am J Clin Dermatol 18, 513–528 (2017). https://doi.org/10.1007/s40257-017-0264-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40257-017-0264-2

Keywords

Search

Navigation